About VBS
Under the ticker VBS, Vectus Biosystems Ltd operates in the Health Care category and is developing treatments for fibrosis, including for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Funds from the IPO and from two subsequent fundraisings were used predominantly to develop the business's lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure.
All News for VBS
No news articles found for VBS yet.